{"id":79197,"topic":"peptides","source":"Sohu","title":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一 - Sohu","url":"https://m.sohu.com/a/1074241147_120244154?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","url_hash":"bb7aa94893f858d9eca8b35e363d2ee593ff3104","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMijAFBVV95cUxPLTRfR2w0Nm1odE9HeDJ3SS11UkpDQXlrblZISHhwNTg5ekRFRTJIdnotVlJhejVNaHpBNFVxV2hmSnczWXJyVEJQeXRDSmE2VVZKd1V0X2J0Tjg4Rk5SVnBkMEMtbEljSkVwb3ZuNnp3Mzk3anJUbGRod09zNVVNUUpfZjhZbG5xejdIYQ?oc=5\" target=\"_blank\">脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Sohu</font>","content":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一\n不少人有的脂肪性肝炎，有了治疗新选择。 9月10日，司美格鲁肽注射液（诺和盈）的代谢相关脂肪性肝炎（MASH）适应症上市申请获得中国国家药品监督管理局批准，成为中国首个且唯一获批用于治疗MASH的GLP-1RA类药物。这也意味着诺和盈成为首个拥有覆盖肥胖症、心血管和代谢相关脂肪性肝炎三大代谢疾病领域证据体系的GLP-1RA类药物。\n中国约三分之一成人患有脂肪肝，警惕沉默中进展的代谢危机\n我国是全球代谢相关脂肪性肝病（MASLD）负担最重的国家之一。据统计，中国有约三分之一成年人患有脂肪肝。在我国超重或肥胖人群中，脂肪肝患病率高达81.8%，并呈上升趋势。脂肪肝已成为当代人体检单上的“常客”，不过，由于身体往往没有明显不适，不少人即使查出脂肪肝，也觉得“没什么大不了”，并未进行进一步检查和干预。\n事实上，肝脏作为人体代谢中心，就像一座“回收处理站”，一旦功能障碍，各类代谢产物和毒素就无法被清理和排出，从而引发全身性的连锁健康危机。比如，随着肝脏脂肪持续过度堆积，脂肪肝将进一步发展为代谢相关脂肪性肝炎（MASH），这一阶段是肝脏从“可逆转单纯脂肪堆积”跨入“不可逆肝损伤”的重要分水岭，如错过这一关键干预窗口，最终可能导致肝硬化、肝癌等致命后果。","image_url":"https://q4.itc.cn/q_70/images03/20260910/7b68602c87e44122ae83e29ea843d323.jpeg","lang":"zh","published_at":"2026-09-10T05:50:36+00:00","fetched_at":"2026-09-10T06:15:13+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一\n不少人有的脂肪性肝炎，有了治疗新选择。…","cluster_id":3527747,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://m.sohu.com/a/1074241147_120244154?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 561 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":561,"summary_length":53,"usable_text_length":561,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":561,"summary_length":53}},"news_item":{"id":79197,"canonical_url":"https://m.sohu.com/a/1074241147_120244154?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source_url":"https://m.sohu.com/a/1074241147_120244154?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","title":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一 - Sohu","source_name":"Sohu","author":null,"published_at":"2026-09-10T05:50:36+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMijAFBVV95cUxPLTRfR2w0Nm1odE9HeDJ3SS11UkpDQXlrblZISHhwNTg5ekRFRTJIdnotVlJhejVNaHpBNFVxV2hmSnczWXJyVEJQeXRDSmE2VVZKd1V0X2J0Tjg4Rk5SVnBkMEMtbEljSkVwb3ZuNnp3Mzk3anJUbGRod09zNVVNUUpfZjhZbG5xejdIYQ?oc=5\" target=\"_blank\">脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Sohu</font>","full_text":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一\n不少人有的脂肪性肝炎，有了治疗新选择。 9月10日，司美格鲁肽注射液（诺和盈）的代谢相关脂肪性肝炎（MASH）适应症上市申请获得中国国家药品监督管理局批准，成为中国首个且唯一获批用于治疗MASH的GLP-1RA类药物。这也意味着诺和盈成为首个拥有覆盖肥胖症、心血管和代谢相关脂肪性肝炎三大代谢疾病领域证据体系的GLP-1RA类药物。\n中国约三分之一成人患有脂肪肝，警惕沉默中进展的代谢危机\n我国是全球代谢相关脂肪性肝病（MASLD）负担最重的国家之一。据统计，中国有约三分之一成年人患有脂肪肝。在我国超重或肥胖人群中，脂肪肝患病率高达81.8%，并呈上升趋势。脂肪肝已成为当代人体检单上的“常客”，不过，由于身体往往没有明显不适，不少人即使查出脂肪肝，也觉得“没什么大不了”，并未进行进一步检查和干预。\n事实上，肝脏作为人体代谢中心，就像一座“回收处理站”，一旦功能障碍，各类代谢产物和毒素就无法被清理和排出，从而引发全身性的连锁健康危机。比如，随着肝脏脂肪持续过度堆积，脂肪肝将进一步发展为代谢相关脂肪性肝炎（MASH），这一阶段是肝脏从“可逆转单纯脂肪堆积”跨入“不可逆肝损伤”的重要分水岭，如错过这一关键干预窗口，最终可能导致肝硬化、肝癌等致命后果。","excerpt":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一\n不少人有的脂肪性肝炎，有了治疗新选择。…","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 561 characters.","diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1074241147_120244154%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 561 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":561,"summary_length":53,"usable_text_length":561,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":561,"summary_length":53}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一 - Sohu","url":"https://m.sohu.com/a/1074241147_120244154?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","summary":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一\n不少人有的脂肪性肝炎，有了治疗新选择。…","source":"Sohu","date":"2026-09-10T05:50:36+00:00","content":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一\n不少人有的脂肪性肝炎，有了治疗新选择。 9月10日，司美格鲁肽注射液（诺和盈）的代谢相关脂肪性肝炎（MASH）适应症上市申请获得中国国家药品监督管理局批准，成为中国首个且唯一获批用于治疗MASH的GLP-1RA类药物。这也意味着诺和盈成为首个拥有覆盖肥胖症、心血管和代谢相关脂肪性肝炎三大代谢疾病领域证据体系的GLP-1RA类药物。\n中国约三分之一成人患有脂肪肝，警惕沉默中进展的代谢危机\n我国是全球代谢相关脂肪性肝病（MASLD）负担最重的国家之一。据统计，中国有约三分之一成年人患有脂肪肝。在我国超重或肥胖人群中，脂肪肝患病率高达81.8%，并呈上升趋势。脂肪肝已成为当代人体检单上的“常客”，不过，由于身体往往没有明显不适，不少人即使查出脂肪肝，也觉得“没什么大不了”，并未进行进一步检查和干预。\n事实上，肝脏作为人体代谢中心，就像一座“回收处理站”，一旦功能障碍，各类代谢产物和毒素就无法被清理和排出，从而引发全身性的连锁健康危机。比如，随着肝脏脂肪持续过度堆积，脂肪肝将进一步发展为代谢相关脂肪性肝炎（MASH），这一阶段是肝脏从“可逆转单纯脂肪堆积”跨入“不可逆肝损伤”的重要分水岭，如错过这一关键干预窗口，最终可能导致肝硬化、肝癌等致命后果。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1074241147_120244154%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 561 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 561 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":561,"summary_length":53,"usable_text_length":561,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":561,"summary_length":53}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/79197","export_markdown":"/api/items/79197/export?format=markdown","export_json":"/api/items/79197/export?format=json","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1074241147_120244154%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"},"formats":{"full":{"id":79197,"title":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一 - Sohu","url":"https://m.sohu.com/a/1074241147_120244154?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source":"Sohu","author":null,"published_at":"2026-09-10T05:50:36+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一\n不少人有的脂肪性肝炎，有了治疗新选择。…","full_text":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一\n不少人有的脂肪性肝炎，有了治疗新选择。 9月10日，司美格鲁肽注射液（诺和盈）的代谢相关脂肪性肝炎（MASH）适应症上市申请获得中国国家药品监督管理局批准，成为中国首个且唯一获批用于治疗MASH的GLP-1RA类药物。这也意味着诺和盈成为首个拥有覆盖肥胖症、心血管和代谢相关脂肪性肝炎三大代谢疾病领域证据体系的GLP-1RA类药物。\n中国约三分之一成人患有脂肪肝，警惕沉默中进展的代谢危机\n我国是全球代谢相关脂肪性肝病（MASLD）负担最重的国家之一。据统计，中国有约三分之一成年人患有脂肪肝。在我国超重或肥胖人群中，脂肪肝患病率高达81.8%，并呈上升趋势。脂肪肝已成为当代人体检单上的“常客”，不过，由于身体往往没有明显不适，不少人即使查出脂肪肝，也觉得“没什么大不了”，并未进行进一步检查和干预。\n事实上，肝脏作为人体代谢中心，就像一座“回收处理站”，一旦功能障碍，各类代谢产物和毒素就无法被清理和排出，从而引发全身性的连锁健康危机。比如，随着肝脏脂肪持续过度堆积，脂肪肝将进一步发展为代谢相关脂肪性肝炎（MASH），这一阶段是肝脏从“可逆转单纯脂肪堆积”跨入“不可逆肝损伤”的重要分水岭，如错过这一关键干预窗口，最终可能导致肝硬化、肝癌等致命后果。","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 561 characters.","diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1074241147_120244154%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 561 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":561,"summary_length":53,"usable_text_length":561,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":561,"summary_length":53}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 561 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":561,"summary_length":53,"usable_text_length":561,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":561,"summary_length":53}},"actions":{"read":"/item/79197","export_markdown":"/api/items/79197/export?format=markdown","export_json":"/api/items/79197/export?format=json","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1074241147_120244154%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"}},"digest":{"id":79197,"title":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一 - Sohu","url":"https://m.sohu.com/a/1074241147_120244154?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source":"Sohu","topic":"peptides","published_at":"2026-09-10T05:50:36+00:00","excerpt":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一 不少人有的脂肪性肝炎，有了治疗新选择。…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 561 characters.","reading_time_min":1,"cluster_id":3527747},"card":{"display_title":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一 - Sohu","subtitle":"Sohu · 2026-09-10","summary":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一 不少人有的脂肪性肝炎，有了治疗新选择。…","badges":["quality:high"],"links":{"read":"/item/79197","original":"https://m.sohu.com/a/1074241147_120244154?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1074241147_120244154%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"},"quality_warning":null},"export":{"title":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一 - Sohu","url":"https://m.sohu.com/a/1074241147_120244154?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","summary":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一\n不少人有的脂肪性肝炎，有了治疗新选择。…","source":"Sohu","date":"2026-09-10T05:50:36+00:00","content":"脂肪肝新治疗来了，司美格鲁肽注射液拿下重磅适应症，中国首个且唯一\n不少人有的脂肪性肝炎，有了治疗新选择。 9月10日，司美格鲁肽注射液（诺和盈）的代谢相关脂肪性肝炎（MASH）适应症上市申请获得中国国家药品监督管理局批准，成为中国首个且唯一获批用于治疗MASH的GLP-1RA类药物。这也意味着诺和盈成为首个拥有覆盖肥胖症、心血管和代谢相关脂肪性肝炎三大代谢疾病领域证据体系的GLP-1RA类药物。\n中国约三分之一成人患有脂肪肝，警惕沉默中进展的代谢危机\n我国是全球代谢相关脂肪性肝病（MASLD）负担最重的国家之一。据统计，中国有约三分之一成年人患有脂肪肝。在我国超重或肥胖人群中，脂肪肝患病率高达81.8%，并呈上升趋势。脂肪肝已成为当代人体检单上的“常客”，不过，由于身体往往没有明显不适，不少人即使查出脂肪肝，也觉得“没什么大不了”，并未进行进一步检查和干预。\n事实上，肝脏作为人体代谢中心，就像一座“回收处理站”，一旦功能障碍，各类代谢产物和毒素就无法被清理和排出，从而引发全身性的连锁健康危机。比如，随着肝脏脂肪持续过度堆积，脂肪肝将进一步发展为代谢相关脂肪性肝炎（MASH），这一阶段是肝脏从“可逆转单纯脂肪堆积”跨入“不可逆肝损伤”的重要分水岭，如错过这一关键干预窗口，最终可能导致肝硬化、肝癌等致命后果。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1074241147_120244154%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 561 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 561 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":561,"summary_length":53,"usable_text_length":561,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":561,"summary_length":53}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}